3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphedema
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Glioblastoma
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Encopresis
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Breast Cancer Female
1
Interventions
Gemcitabine
42
130-nm albumin-bound paclitaxel
26
Albumin-Bound Paclitaxel
18
Irinotecan
16
Oxaliplatin
14
Fluorouracil
14
pembrolizumab
13
Nivolumab
13
Magnetic Resonance Spectroscopy
11
Leucovorin
11
Taxes
10
Specimen Handling
9
Biopsy
9
Cisplatin
8
Capecitabine
7
folfirinox
6
Radiotherapy
6
Carboplatin
6
irinotecan sucrosofate
5
durvalumab
5
Ipilimumab
5
Cyclophosphamide
5
olaparib
4
defactinib
4
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Immunoglobulin G
4
Disulfides
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pancreatic Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT04106856
2026-05-12
SHAPER
University of Utah
Phase 1
Active not recruiting
22 enrolled